David Barch

Statistics

Publications

Citations

268

H-Index

Active since

1985

Affiliations

AbbVie (United States)(Current)

Dana-Farber Cancer Institute

Hospital Universitario Fundación Jiménez Díaz

South Texas Accelerated Research Therapeutics

David Barch is an author at AbbVie (United States) specializing in egfr inhibition, antibody-drug conjugate pharmacokinetics, and therapeutic monoclonal antibodies.

Publications per year

1985–2020

Publications

Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

Angelo Antonini, Werner Poewe, К. Ray Chaudhuri et al. · Parkinsonism & Related Disorders · 2017 · 210 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

James M. Cleary, Emiliano Calvo, Víctor Moreno et al. · Investigational New Drugs · 2020 · 31 citations

Medicine, Oncology, Pharmacokinetics +17

A qualitative agar gel immunoprecipitin (IP) test for detection of fecal occult human hemoglobin

Yung D. Kim, Julie M. Nolan, Aaron Malkin et al. · Clinica Chimica Acta · 1985 · 15 citations

Life Sciences, Microbiology, Diagnostic Microbiology +13

Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.

Emiliano Calvo, James M. Cleary, Víctor Moreno et al. · Journal of Clinical Oncology · 2017 · 12 citations

Pharmacy, Oncology, Pharmacology +17

1–4 of 4